CPHIHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 1 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores China Pharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (82): The business earns solid, repeatable profits on what it owns.
Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own China Pharma Holdings, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on CPHI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 84% of US stocks
Cheaper than 13% of US stocks
Cheaper than 66% of US stocks
Cheaper than 93% of US stocks
Higher than 13% of US stocks
Higher than 23% of US stocks
Higher than 35% of US stocks
Higher than 13% of US stocks
Higher than 6% of US stocks
Higher than 32% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CPHI appears on the weeks it earns a place.
China Pharma Holdings, Inc. announced the closing of a registered direct offering of 2,500,000 shares of common stock at $2.00 per share, generating gross proceeds of $5 million before fees and expenses.
Why it matters — This offering provides CPHI with $5 million in gross proceeds, which could be used for working capital or other corporate purposes.
As at 1 Aug 2026, China Pharma Holdings, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (82 of 100).
No analyst covering China Pharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CPHI are extrapolating price history, which says nothing about the business.
China Pharma Holdings Inc. is a pharmaceutical company focused on the development, manufacture, and marketing of drugs and healthcare products in China.
The most recent item we track (PRNewsWire, 23 July 2026): "China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering". China Pharma Holdings, Inc. announced the closing of a registered direct offering of 2,500,000 shares of common stock at $2.00 per share, generating gross proceeds of $5 million before fees and expenses.
China Pharma Holdings Inc. is a pharmaceutical company focused on the development, manufacture, and marketing of drugs and healthcare products in China. Through its wholly owned subsidiary, Hainan Helpson Medicine & Biotechnique Co., Ltd., the company operates an integrated business covering research and development, production, and sales. Its portfolio includes products for cardiovascular, central nervous system, infectious, respiratory, and digestive diseases, along with comprehensive healthcare and protective products. China Pharma Holdings Inc. works primarily with dosage forms such as injectables, tablets, capsules, and oral solutions, serving hospitals, retailers, and other healthcare channels. The company is based in Haikou, Hainan, and plays a specialized role in supplying medicines aimed at conditions with significant prevalence in the Chinese market.
CEO Ms. Zhilin Li · 215 employees · China · https://www.chinapharmaholdings.com